Differential Inhibition of Primary versus Preactivated T Cells by Pimecrolimus but Not by Tacrolimus in vitro
Background: Recent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not inhibit the sensitization phase, whereas both compounds equivalently suppressed the inflammatory response in sensitized animals. This find...
Saved in:
Published in | International Archives of Allergy and Immunology Vol. 142; no. 3; pp. 255 - 264 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel, Switzerland
Karger
01.01.2007
S. Karger AG |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Recent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not inhibit the sensitization phase, whereas both compounds equivalently suppressed the inflammatory response in sensitized animals. This finding indicated a differential sensitivity of antigen-naïve and primed T cells towards pimecrolimus and tacrolimus. Methods: T cells obtained from healthy and allergic donors were subjected to primary and secondary stimulation by allogeneic or staphylococcal superantigen-presenting dendritic cells (DC). Human skin-derived, allergen-specific T cell clones from an atopic dermatitis patient were activated by anti-CD3 antibodies or by specific allergen-presenting DC. The inhibition of T cell proliferation and cytokine release by graded doses of calcineurin inhibitors was evaluated. Results: Primary stimulation of T cells was inhibited by pimecrolimus with an approximately 8-fold lower potency as compared with tacrolimus. In contrast, the secondary response of ex vivo expanded T cells activated by allogeneic or staphylococcal superantigen-presenting DC was inhibited by both compounds with equivalent potency. Likewise, both drugs showed very similar potency to inhibit the proliferation and cytokine synthesis from antigen- stimulated T cell clones and the induction of cytokines in Jurkat T cells. Conclusion: These data indicate that pimecrolimus has a selectivity for antigen-primed memory T cells not seen with tacrolimus. |
---|---|
AbstractList | Recent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not inhibit the sensitization phase, whereas both compounds equivalently suppressed the inflammatory response in sensitized animals. This finding indicated a differential sensitivity of antigen-naïve and primed T cells towards pimecrolimus and tacrolimus.
T cells obtained from healthy and allergic donors were subjected to primary and secondary stimulation by allogeneic or staphylococcal superantigen-presenting dendritic cells (DC). Human skin-derived, allergen-specific T cell clones from an atopic dermatitis patient were activated by anti-CD3 antibodies or by specific allergen-presenting DC. The inhibition of T cell proliferation and cytokine release by graded doses of calcineurin inhibitors was evaluated.
Primary stimulation of T cells was inhibited by pimecrolimus with an approximately 8-fold lower potency as compared with tacrolimus. In contrast, the secondary response of ex vivo expanded T cells activated by allogeneic or staphylococcal superantigen-presenting DC was inhibited by both compounds with equivalent potency. Likewise, both drugs showed very similar potency to inhibit the proliferation and cytokine synthesis from antigen- stimulated T cell clones and the induction of cytokines in Jurkat T cells.
These data indicate that pimecrolimus has a selectivity for antigen-primed memory T cells not seen with tacrolimus. Background: Recent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not inhibit the sensitization phase, whereas both compounds equivalently suppressed the inflammatory response in sensitized animals. This finding indicated a differential sensitivity of antigen-naïve and primed T cells towards pimecrolimus and tacrolimus. Methods: T cells obtained from healthy and allergic donors were subjected to primary and secondary stimulation by allogeneic or staphylococcal superantigen-presenting dendritic cells (DC). Human skin-derived, allergen-specific T cell clones from an atopic dermatitis patient were activated by anti-CD3 antibodies or by specific allergen-presenting DC. The inhibition of T cell proliferation and cytokine release by graded doses of calcineurin inhibitors was evaluated. Results: Primary stimulation of T cells was inhibited by pimecrolimus with an approximately 8-fold lower potency as compared with tacrolimus. In contrast, the secondary response of ex vivo expanded T cells activated by allogeneic or staphylococcal superantigen-presenting DC was inhibited by both compounds with equivalent potency. Likewise, both drugs showed very similar potency to inhibit the proliferation and cytokine synthesis from antigen- stimulated T cell clones and the induction of cytokines in Jurkat T cells. Conclusion: These data indicate that pimecrolimus has a selectivity for antigen-primed memory T cells not seen with tacrolimus. Background: Recent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not inhibit the sensitization phase, whereas both compounds equivalently suppressed the inflammatory response in sensitized animals. This finding indicated a differential sensitivity of antigen-naive and primed T cells towards pimecrolimus and tacrolimus. Methods: T cells obtained from healthy and allergic donors were subjected to primary and secondary stimulation by allogeneic or staphylococcal superantigen-presenting dendritic cells (DC). Human skin-derived, allergen-specific T cell clones from an atopic dermatitis patient were activated by anti-CD3 antibodies or by specific allergen-presenting DC. The inhibition of T cell proliferation and cytokine release by graded doses of calcineurin inhibitors was evaluated. Results: Primary stimulation of T cells was inhibited by pimecrolimus with an approximately 8-fold lower potency as compared with tacrolimus. In contrast, the secondary response of ex vivo expanded T cells activated by allogeneic or staphylococcal superantigen-presenting DC was inhibited by both compounds with equivalent potency. Likewise, both drugs showed very similar potency to inhibit the proliferation and cytokine synthesis from antigen-stimulated T cell clones and the induction of cytokines in Jurkat T cells. Conclusion: These data indicate that pimecrolimus has a selectivity for antigen-primed memory T cells not seen with tacrolimus. Background: Recent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not inhibit the sensitization phase, whereas both compounds equivalently suppressed the inflammatory response in sensitized animals. This finding indicated a differential sensitivity of antigen-naive and primed T cells towards pimecrolimus and tacrolimus. Methods: T cells obtained from healthy and allergic donors were subjected to primary and secondary stimulation by allogeneic or staphylococcal superantigen-presenting dendritic cells (DC). Human skin-derived, allergen-specific T cell clones from an atopic dermatitis patient were activated by anti-CD3 antibodies or by specific allergen-presenting DC. The inhibition of T cell proliferation and cytokine release by graded doses of calcineurin inhibitors was evaluated. Results: Primary stimulation of T cells was inhibited by pimecrolimus with an approximately 8-fold lower potency as compared with tacrolimus. In contrast, the secondary response of ex vivo expanded T cells activated by allogeneic or staphylococcal superantigen-presenting DC was inhibited by both compounds with equivalent potency. Likewise, both drugs showed very similar potency to inhibit the proliferation and cytokine synthesis from antigen- stimulated T cell clones and the induction of cytokines in Jurkat T cells. Conclusion: These data indicate that pimecrolimus has a selectivity for antigen-primed memory T cells not seen with tacrolimus. [PUBLICATION ABSTRACT] BACKGROUNDRecent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not inhibit the sensitization phase, whereas both compounds equivalently suppressed the inflammatory response in sensitized animals. This finding indicated a differential sensitivity of antigen-naïve and primed T cells towards pimecrolimus and tacrolimus.METHODST cells obtained from healthy and allergic donors were subjected to primary and secondary stimulation by allogeneic or staphylococcal superantigen-presenting dendritic cells (DC). Human skin-derived, allergen-specific T cell clones from an atopic dermatitis patient were activated by anti-CD3 antibodies or by specific allergen-presenting DC. The inhibition of T cell proliferation and cytokine release by graded doses of calcineurin inhibitors was evaluated.RESULTSPrimary stimulation of T cells was inhibited by pimecrolimus with an approximately 8-fold lower potency as compared with tacrolimus. In contrast, the secondary response of ex vivo expanded T cells activated by allogeneic or staphylococcal superantigen-presenting DC was inhibited by both compounds with equivalent potency. Likewise, both drugs showed very similar potency to inhibit the proliferation and cytokine synthesis from antigen- stimulated T cell clones and the induction of cytokines in Jurkat T cells.CONCLUSIONThese data indicate that pimecrolimus has a selectivity for antigen-primed memory T cells not seen with tacrolimus. |
Author | Wang, Shirley Weishaeupl, Cordula Winiski, Anthony Fichtinger, Petra Schwendinger, Brigitte Stuetz, Anton Kalthoff, Frank S. |
Author_xml | – sequence: 1 givenname: Frank S. surname: Kalthoff fullname: Kalthoff, Frank S. – sequence: 2 givenname: Anthony surname: Winiski fullname: Winiski, Anthony – sequence: 3 givenname: Petra surname: Fichtinger fullname: Fichtinger, Petra – sequence: 4 givenname: Brigitte surname: Schwendinger fullname: Schwendinger, Brigitte – sequence: 5 givenname: Shirley surname: Wang fullname: Wang, Shirley – sequence: 6 givenname: Cordula surname: Weishaeupl fullname: Weishaeupl, Cordula – sequence: 7 givenname: Anton surname: Stuetz fullname: Stuetz, Anton |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18496018$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17114891$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0c2P1CAUAHBi1rgfevBsYoiJJh6qPEopHM24q5tsdA_juaHtQ1lbWIFOsv-9TDqZTbwIB3jklwePd05OfPBIyEtgHwAa_ZGVoVvG1RNyBoLX1T48KXsGquKiVqfkPKU7xgpW8hk5hRZAKA1nZP7srMWIPjsz0Wv_y_Uuu-BpsPQ2utnEB7rDmJZUQjRDdjuTcaRbusFpSrR_oLduxiGGyc0F9Uum30Len2_N8dR5unM5hufkqTVTwheH9YL8uLrcbr5WN9-_XG8-3VRDrSFXo2SS61ZLKQE0r1krtEXsoTHWWi5GzkULiLLFWhlmG2xs37cjDFIoGMf6grxb897H8GfBlLvZpaE82HgMS-qkZtAyIf8LOSuTN3v45h94F5boSxEd56BYo4Uu6P2KSuEpRbTd_fqFHbBu36nu2KliXx8SLv2M46M8tKaAtwdg0mAmG40fXHp0SmhZ-lvcq9X9NvEnxiNYr_kLAC6kpA |
CitedBy_id | crossref_primary_10_1084_jem_20081747 crossref_primary_10_1124_dmd_108_021915 crossref_primary_10_1345_aph_1M278 crossref_primary_10_2165_10481960_000000000_00000 crossref_primary_10_3109_09546634_2016_1163317 crossref_primary_10_1038_jid_2009_50 crossref_primary_10_1586_17469872_2013_835923 crossref_primary_10_1517_14656560802498040 crossref_primary_10_2217_17455111_1_2_149 crossref_primary_10_1007_s40257_023_00787_3 crossref_primary_10_3390_pharmaceutics15041278 |
Cites_doi | 10.1016%2F0092-8674%2891%2990124-H 10.1016%2FS0091-6749%2899%2970294-0 10.1016%2Fj.jaci.2004.05.066 10.1046%2Fj.1523-1747.2002.00694.x 10.1002%2Feji.1830210228 10.1046%2Fj.1365-2249.2002.01962.x 10.1046%2Fj.1523-1747.2003.12331.x 10.1146%2Fannurev.immunol.15.1.707 10.1111%2Fj.1365-2133.2005.06674.x 10.1074%2Fjbc.273.22.13367 10.1016%2FS0898-6568%2898%2900019-9 10.1016%2F0091-6749%2892%2990070-I 10.1016%2FS0966-3274%2896%2980038-4 10.1016%2Fj.jaci.2005.02.011 10.1111%2Fj.1365-2133.2005.06661.x 10.1046%2Fj.1365-2249.2003.02225.x 10.1111%2Fj.1398-9995.2005.00798.x 10.1159%2F000024051 10.1016%2FS0198-8859%2800%2900137-3 10.1046%2Fj.1365-2133.1999.02974.x 10.1097%2F00007890-199011000-00016 |
ContentType | Journal Article |
Copyright | 2007 S. Karger AG, Basel 2007 INIST-CNRS Copyright (c) 2007 S. Karger AG, Basel |
Copyright_xml | – notice: 2007 S. Karger AG, Basel – notice: 2007 INIST-CNRS – notice: Copyright (c) 2007 S. Karger AG, Basel |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T5 7U9 7X7 7XB 88E 8AO 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M7P MBDVC PQEST PQQKQ PQUKI PRINS Q9U 7QL C1K 7X8 |
DOI | 10.1159/000097028 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Immunology Abstracts Virology and AIDS Abstracts ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Medical Database Proquest Research Library Biological Science Database Research Library (Corporate) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest Central (Alumni) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef AIDS and Cancer Research Abstracts Research Library Prep MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1423-0097 1365-2567 |
EndPage | 264 |
ExternalDocumentID | 1219228891 10_1159_000097028 17114891 18496018 97028 |
Genre | Journal Article Comparative Study |
GroupedDBID | --- .55 .GJ 0R~ 0~5 0~B 29J 30W 328 34G 36B 39C 3O- 3O. 3V. 4.4 53G 5GY 5RE 7X7 88E 8AO 8FE 8FH 8FI 8FJ 8G5 8UI AAYIC ABJNI ABOCM ABPAZ ABUWG ACGFS ACPRK ACPSR ADAGL ADBBV AENEX AEYAO AFDXO AFFNX AFJJK AFKRA AFRAH AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BBNVY BENPR BHPHI BPHCQ BVXVI CAG CCPQU COF CS3 CYUIP DU5 DWQXO E0A EBS EJD EMB EMOBN F5P FB. FYUFA GNUQQ GUQSH HCIFZ HMCUK HZ~ IAO IHR IHW INH IY7 KUZGX L7B LK8 M1P M2O M7P N9A O1H O9- PQQKQ PROAC PSQYO RIG RKO RXVBD SV3 UJ6 UKHRP X7M ZGI ZXP AAKET AAUGY ABPTK ABZSI ACHQM IQODW CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION 7T5 7U9 7XB 8FK H94 K9. MBDVC PQEST PQUKI PRINS Q9U 7QL C1K 7X8 |
ID | FETCH-LOGICAL-c391t-d6062979666119230749feeb15afff24d22471ee67e38a0f5e5fbb7d1c6481dd3 |
IEDL.DBID | BENPR |
ISSN | 1018-2438 |
IngestDate | Fri Aug 16 04:20:16 EDT 2024 Fri Jun 28 08:59:00 EDT 2024 Thu Oct 10 16:51:05 EDT 2024 Wed Sep 18 12:52:25 EDT 2024 Sat Sep 28 07:51:49 EDT 2024 Sun Oct 22 16:06:54 EDT 2023 Thu Aug 29 12:04:47 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Primary response Pimecrolimus Tacrolimus T cell Recall response Immunopathology Lactone Macrolide In vitro Immunology T-Lymphocyte Primary Recall Protein synthesis inhibitor Immunosuppressive agent Comparative study |
Language | English |
License | Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c391t-d6062979666119230749feeb15afff24d22471ee67e38a0f5e5fbb7d1c6481dd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17114891 |
PQID | 221805949 |
PQPubID | 41082 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_20202256 proquest_journals_221805949 proquest_miscellaneous_69017046 pubmed_primary_17114891 pascalfrancis_primary_18496018 karger_primary_97028 crossref_primary_10_1159_000097028 |
PublicationCentury | 2000 |
PublicationDate | 2007-01-01 |
PublicationDateYYYYMMDD | 2007-01-01 |
PublicationDate_xml | – month: 01 year: 2007 text: 2007-01-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Basel, Switzerland |
PublicationPlace_xml | – name: Basel, Switzerland – name: Basel – name: Switzerland |
PublicationTitle | International Archives of Allergy and Immunology |
PublicationTitleAlternate | Int Arch Allergy Immunol |
PublicationYear | 2007 |
Publisher | Karger S. Karger AG |
Publisher_xml | – name: Karger – name: S. Karger AG |
References | Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-273.1046879810.1046%2Fj.1365-2133.1999.02974.x Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne JP, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF: Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 2005;152:1219-1227.1594898510.1111%2Fj.1365-2133.2005.06661.x Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, Kehren J, Chibout SD, Cordier A, Holter W, Richter L, Oberbauer R, Stuetz A, Wolff K: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-887.1240633410.1046%2Fj.1523-1747.2002.00694.x Kalthoff FS, Chung J, Stuetz A: Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin Exp Immunol 2002;130:85-92.1229685710.1046%2Fj.1365-2249.2002.01962.x Schwinzer R, Siefken R: CD45RA+ and CD45RO+ T cells differ in susceptibility to cyclosporin A mediated inhibition of interleukin-2 production. Transpl Immunol 1996;4:61-63.876201410.1016%2FS0966-3274%2896%2980038-4 Wolff K, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M, Shear N, Silny W, Korman N, Marks I, Cherill R, Emady-Azar S, Paul CF: Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005;152:1296-1303.1594899610.1111%2Fj.1365-2133.2005.06674.x Akdis CA, Akdis M, Simon HU, Blaser K: Regulation of allergic inflammation by skin-homing T cells in allergic eczema. Int Arch Allergy Immunol 1999;118:140-144.1022436210.1159%2F000024051 Winiski A, Wang S, Schwendinger B, Stuetz A: Inhibitory activity of pimecrolimus and tacrolimus on induced cytokine mRNA and protein expression in a human T cell line (Jurkat) measured via RT PCR and ELISA (abstract). J Invest Dermatol 2002;119:347. Akbar AN, Amlot PL, Ivory K, Timms A, Janossy G: Inhibition of alloresponsive naive and memory T cells by CD7 and CD25 antibodies and by cyclosporine. Transplantation 1990;50:823-829.170050610.1097%2F00007890-199011000-00016 Meingassner JG, Fahrngruber H, Bavandi A: Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporin A. J Invest Dermatol 2003;121:77-80.1283956610.1046%2Fj.1523-1747.2003.12331.x Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka JJ, Chin J, Hutchinson NI: The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989;143:718-726.2472451 Masuda ES, Imamura R, Amasaki Y, Arai K, Arai N: Signalling into the T-cell nucleus: NFAT regulation. Cell Signal 1998;10:599-611.979424110.1016%2FS0898-6568%2898%2900019-9 Kalthoff FS, Chung J, Musser P, Stuetz A: Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003;133:350-359.1293036010.1046%2Fj.1365-2249.2003.02225.x Pacocha SE, Oriente A, Huang SK, Essayan DM: Regulation of antigen-induced human T-lymphocyte responses by calcineurin antagonists. J Allergy Clin Immunol 1999;104:828-835.1051882810.1016%2FS0091-6749%2899%2970294-0 Marsland AM, Griffiths CE: The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002;12:618-622.12459545 Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU: Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004;114:887-895.1548033010.1016%2Fj.jaci.2004.05.066 Klee KB, Ren H, Wang X: Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem 1998;273:13367-13370.959366210.1074%2Fjbc.273.22.13367 Rao A, Luo C, Hogan PG: Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997;15:707-747.914370510.1146%2Fannurev.immunol.15.1.707 Bierer BE, Schreiber SL Burakoff SJ: The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. Eur J Immunol 1991;21:439-445.170551310.1002%2Feji.1830210228 Bohle B, Schwihla H, Hu HZ, Friedl-Hajek R, Sowka S, Ferreira F, Breiteneder H, Bruijnzeel-Koomen CA, de Weger RA, Mudde GC, Ebner C, Van Reijsen FC: Long-lived Th2 clones specific for seasonal and perennial allergens can be detected in blood and skin by their TCR-hypervariable regions. J Immunol 1998;160:2022-2027.9469466 Simon D, Vassina E, Yousefi S, Braathen LR, Simon HU: Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 2005;60:944-951.1593238610.1111%2Fj.1398-9995.2005.00798.x Baselmans PJ, Pollabauer E, van Reijsen FC, Heystek HC, Hren A, Stumptner P, Tilanus MG, Vooijs WC, Mudde GC: IgE production after antigen-specific and cognate activation of HLA-DPw4 restricted T cell clones by 78% of randomly selected B cell donors. Hum Immunol 2000;61:789-798.1098038910.1016%2FS0198-8859%2800%2900137-3 Van Reijsen FC, Bruijnzeel-Koomen CA, Kalthoff FS, Maggi E, Romagnani S, Westland JK, Mudde GC: Skin-derived aeroallergen-specific T cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992;90:184-193.138001910.1016%2F0091-6749%2892%2990070-I Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-815.171524410.1016%2F0092-8674%2891%2990124-H Henderson DJ, Naya I, Bundick RV, Smith GM, Schmidt JA: Comparison of the effects of FK506, cyclosporin A and rapamycin on IL-2 production. Immunology 1991;73:316-321.1715317 Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Burger A: Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005;115:1276-1283.1594014710.1016%2Fj.jaci.2005.02.011 ref13 ref12 ref15 ref14 ref20 ref11 ref10 ref21 ref2 ref1 ref17 ref16 ref19 ref18 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref2 doi: 10.1016%2F0092-8674%2891%2990124-H – ident: ref12 doi: 10.1016%2FS0091-6749%2899%2970294-0 – ident: ref16 doi: 10.1016%2Fj.jaci.2004.05.066 – ident: ref19 doi: 10.1046%2Fj.1523-1747.2002.00694.x – ident: ref5 doi: 10.1002%2Feji.1830210228 – ident: ref7 doi: 10.1046%2Fj.1365-2249.2002.01962.x – ident: ref8 doi: 10.1046%2Fj.1523-1747.2003.12331.x – ident: ref4 doi: 10.1146%2Fannurev.immunol.15.1.707 – ident: ref21 doi: 10.1111%2Fj.1365-2133.2005.06674.x – ident: ref1 doi: 10.1074%2Fjbc.273.22.13367 – ident: ref3 doi: 10.1016%2FS0898-6568%2898%2900019-9 – ident: ref9 doi: 10.1016%2F0091-6749%2892%2990070-I – ident: ref14 doi: 10.1016%2FS0966-3274%2896%2980038-4 – ident: ref17 doi: 10.1016%2Fj.jaci.2005.02.011 – ident: ref20 doi: 10.1111%2Fj.1365-2133.2005.06661.x – ident: ref11 doi: 10.1046%2Fj.1365-2249.2003.02225.x – ident: ref18 doi: 10.1111%2Fj.1398-9995.2005.00798.x – ident: ref15 doi: 10.1159%2F000024051 – ident: ref10 doi: 10.1016%2FS0198-8859%2800%2900137-3 – ident: ref6 doi: 10.1046%2Fj.1365-2133.1999.02974.x – ident: ref13 doi: 10.1097%2F00007890-199011000-00016 |
SSID | ssj0015986 ssj0013055 |
Score | 1.9168881 |
Snippet | Background: Recent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did... Recent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not inhibit... BACKGROUNDRecent studies in murine models of allergic contact dermatitis have shown that systemic treatment with pimecrolimus in contrast to tacrolimus did not... |
SourceID | proquest crossref pubmed pascalfrancis karger |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 255 |
SubjectTerms | Allergies Biological and medical sciences Cell Line Cell Proliferation - drug effects Cloning Cytokines Cytokines - biosynthesis Cytokines - drug effects Dendritic Cells - immunology Dermatitis Dermatitis, Atopic - immunology Enzyme-Linked Immunosorbent Assay Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunology Immunopathology Immunosuppressive Agents - pharmacology In Vitro Techniques Jurkat Cells Lymphocyte Activation - drug effects Lymphocyte Culture Test, Mixed Medical sciences Original Paper Reverse Transcriptase Polymerase Chain Reaction Rodents T-Lymphocytes - drug effects Tacrolimus - analogs & derivatives Tacrolimus - pharmacology |
Title | Differential Inhibition of Primary versus Preactivated T Cells by Pimecrolimus but Not by Tacrolimus in vitro |
URI | https://karger.com/doi/10.1159/000097028 https://www.ncbi.nlm.nih.gov/pubmed/17114891 https://www.proquest.com/docview/221805949 https://search.proquest.com/docview/20202256 https://search.proquest.com/docview/69017046 |
Volume | 142 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swELcGRWgvE-NrHaxYiNeIOHXi-GnaOhhDoqpQkfoWxbEtItoEmhSJ_353iRvYA3v05RQrZ_v8u4_cEXIWGNEUnPQYgGGPM5F6cagCz9e-iTJlDM_QNXAzjq7u-PUsnLncnMqlVa51YqOodZmhj_w8gLsIa4vI749PHjaNwuCq66CxQXoB4xil7f28GE9uuzACFh9vwp0MtgMfxq60ENCbqo1S-NiF_c2FtPWA-ddLzJBMKxCSbbtbvA8_m2vocod8cviR_mgX_DP5YIpdsn3jIuR7ZPHLdTyBkzunf4r7XDVJWbS0dNJWlqCYibGqYGjwr4ZnQJuaTunIzOcVVS90ki8AS5bzfAFMalXTcVkjfZp21Lygz3m9LPfJ3eXFdHTluZYKXjaUrPY02CuBFGDjRAyxHQAIaQ3o6zC11gZcw40umDGRMMM49W1oQquU0CyLOCBbPTwgm0VZmC-EZiqy0mYRaAEFmMxKjbGCkMUKS9Zluk9O13JNHtvvSxqLI5RJJ_w-2Wsl3rE48uAf-b--IOZgcjFgOFovSOIOXZV0W6RPTrqncFowBJIWplwBC6Bj0GDR-xzYoEv4HDgO23V-nVug7SjZ1__OfUQ-tu5f9NIck816uTLfALfUakA2xEwM3B6F0e8Z-wt_mu0- |
link.rule.ids | 315,786,790,12083,21416,27955,27956,31752,31753,33777,33778,43343,43838 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED-NMrG9TGPso7CBNe01Wpwmcfw0MQYqg1bVVCTeoji2RbQ2YU2KtP9-d4kbxgM85nJKlLN997uP3AF8CYxoG056HMGwF3KReUmkAs_XvolzZUyYU2hgMo3HV-HP6-ja1ebUrqxyoxNbRa2rnGLkXwO0RdRbRH67_ePR0ChKrroJGluwTR03kwFsfz-dzn71aQRqPt6mOzluB2RxrYWQ3nZtlMKnKez_GaTnv6n-ekUVklmNQrLddIvH4Wdrhs5ewyuHH9lxt-C78MyUb2Bn4jLke7D84Sae4MldsPPyplBtURarLJt1nSUYVWKsa7w09FfDHaJNzebsxCwWNVN_2axYIpasFsUSmdS6YdOqIfo866lFye6KZlW9hauz0_nJ2HMjFbx8JHnjafRXAinQx4k5YTsEENIa1NdRZq0NQo0WXXBjYmFGSebbyERWKaF5HoeIbPXoHQzKqjQfgOUqttLmMWoBhZjMSk25gognilrW5XoInzdyTW-770tbjyOSaS_8Iex1Eu9ZHPnwgfzvH5CE6HJxZDjYLEjqDl2d9ltkCEf9XTwtlALJSlOtkQXRMWqw-HEOGtAl_BA53nfrfP9uQb6j5PtPvvsIXoznk8v08nx6cQAvu1AwRWw-wqBZrc0nxDCNOnQ79R-31O5c |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+inhibition+of+primary+versus+preactivated+T+cells+by+pimecrolimus+but+not+by+tacrolimus+in+vitro&rft.jtitle=International+archives+of+allergy+and+immunology&rft.au=Kalthoff%2C+Frank+S&rft.au=Winiski%2C+Anthony&rft.au=Fichtinger%2C+Petra&rft.au=Schwendinger%2C+Brigitte&rft.date=2007-01-01&rft.issn=1018-2438&rft.volume=142&rft.issue=3&rft.spage=255&rft_id=info:doi/10.1159%2F000097028&rft_id=info%3Apmid%2F17114891&rft.externalDocID=17114891 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1018-2438&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1018-2438&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1018-2438&client=summon |